RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..3 of 3 - per page
Order by
Product enhancement of small and large molecules in a range of dosage forms
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Optimised pulmonary and nasal therapies using supercritical fluid (SCF) particle engineering
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Tackling challenges of poor solubility
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Displaying 1..3 of 3 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
West Nile Virus Global Clinical Trials Review, Q1, 2011
Apr 2011 - 24 pages - $1,000
Epidemiology: Hepatitis C - Hepatitis C virus will remain a prevalent bloodborne disease in the seven major markets, primarily transmitted through injection drug use
Feb 2011 - 26 pages - $5,700
Herpes Simplex Virus Infection Therapy Area Pipeline Report
Nov 2010 - 245 pages - $1,495
Respiratory Syncytial Virus (RSV) Infection Therapy Area Pipeline Report
Nov 2010 - 160 pages - $1,495
Victrelis (boceprevir) - First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor Approved in The US and Telaprevir to Follow
May 2011 - 6 pages - $500
Respiratory Syncytial Virus (RSV) Infection Global Clinical Trials Review, Q4, 2010
Dec 2010 - 48 pages - $1,000
The National Institute of Allergy and Infectious Diseases – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
Respiratory Syncytial Virus (RSV) Infection - Pipeline Review, Q1 2011
Jan 2011 - 33 pages - $500
West Nile Virus Infections - Pipeline Review, Q2 2011
May 2011 - 34 pages - $500
Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
Apr 2010 - 139 pages - $3,800
More Related Market Research Reports >>>

Your selection

Therapeutic target
Infectious diseases del
Bacteria or virus del
Parainfluenza virus (Type 3) del
Development phase
Phase I del

Browse By

Industry sector
Animal health
Biotechnology
Diagnostic
Drug delivery
Drug discovery
Medical device
Pharmaceutical
Research tools

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us